KETAMINE'S THERAPEUTIC POTENTIAL
There has been a surge of interest in ketamine’s use for treatment-resistant depression and PTSD therapy. This clinical interest has been accompanied by an impressive array of biological and behavioral studies corroborating its antidepressant properties. In this talk, we’ll examine the latest research on ketamine’s role in psychiatric treatment. There are currently a variety of routes of administration used for the drug in practice, each with its own advantages and disadvantages. We’ll consider some of these methods and the implications for future treatment in the coming years.
JOHN HARTBERG, B.Sc., is a medical student at the University of Queensland in Brisbane, where he is conducting research at a psychiatric practice using oral ketamine for treatment-resistant depression and PTSD. He holds a B.S. in Neuroscience from the University of Minnesota. John previously served as study coordinator for the MAPS-sponsored MDMA therapy study in Marin County. Prior to that, he held an internship with MAPS and compiled data from ibogaine and MDMA studies. He has an interest in medicine in remote and underserved communities, having worked with underserved communities in the Peruvian Amazon, Cambodia, Standing Rock, and the South Pacific.